Zhai Jin-Hai, Gu Wen-Chao, Xu Xiao-Lin, Wu Jiang, Hu Xue-Jun, Hou Ke-Zhu
GI Medicine, Wuxi TCM Hospital, Wuxi, 214000, People's Republic of China.
Tumour Biol. 2015 Feb;36(2):701-9. doi: 10.1007/s13277-014-2251-z. Epub 2014 Oct 7.
Many studies evaluated the correlations of CD133 expression with the clinical outcomes in patients treated with chemoradiotherapy (CRT) but yielded controversial results. This meta-analysis was performed to identify the impacts of CD133 expression on the prognosis of cancer patients treated with CRT. Electronic databases updated up to March 2014 were searched to find relevant studies. Relevant literatures without any language restrictions were searched via electronic databases as follows: Web of Science (1945 ~ 2013), the Cochrane Library Database (Issue 12, 2013), PubMed (1966 ~ 2013), EMBASE (1980 ~ 2013), CINAHL (1982 ~ 2013), and the Chinese Biomedical Database (CBM) (1982 ~ 2013). STATA software was used for the current meta-analysis. Hazard ratios (HR) and its corresponding 95% confidence interval (95% CI) were calculated. Six studies were identified with a total of 470 cancer patients treated with CRT. The meta-analysis results showed that CD133-positive patients had poorer overall survival (OS) than that of CD133-negative patients (HR = 2.13, 95% CI = 1.20 ~ 3.07, P < 0.001). Furthermore, CD133-positive patients displayed shorter disease-free survival (DFS) than that of CD133-negative patients (HR = 1.74, 95% CI = 0.08 ~ 3.40, P = 0.039). Ethnicity-stratified analysis indicated that CD133 expression positively correlated with shorter OS among the Japanese, Chinese, and Spanish populations (all P < 0.05). In conclusion, our findings suggest that CD133 expression may be positively correlated with poorer prognosis in cancer patients treated with CRT.
许多研究评估了CD133表达与接受放化疗（CRT）患者临床结局的相关性，但结果存在争议。本荟萃分析旨在确定CD133表达对接受CRT治疗的癌症患者预后的影响。检索了截至2014年3月更新的电子数据库以查找相关研究。通过以下电子数据库检索无任何语言限制的相关文献：科学网（1945年至2013年）、考克兰图书馆数据库（2013年第12期）、PubMed（1966年至2013年）、EMBASE（1980年至2013年）、CINAHL（1982年至2013年）以及中国生物医学数据库（CBM）（1982年至2013年）。使用STATA软件进行本次荟萃分析。计算风险比（HR）及其相应的95%置信区间（95%CI）。确定了6项研究，共有470例接受CRT治疗的癌症患者。荟萃分析结果显示，CD133阳性患者的总生存期（OS）比CD133阴性患者差（HR = 2.13，95%CI = 1.20至3.07，P < 0.001）。此外，CD133阳性患者的无病生存期（DFS）比CD133阴性患者短（HR = 1.74，95%CI = 0.08至3.40，P = 0.039）。种族分层分析表明，在日本、中国和西班牙人群中，CD133表达与较短的OS呈正相关（所有P < 0.05）。总之，我们的研究结果表明，CD133表达可能与接受CRT治疗的癌症患者较差的预后呈正相关。
